title: [Evaluation of pancreatic scintigram in the diagnosis of pancreatic diseases (author's transl)].
abstract: The classification of accumulative patterns with the pancreatic scintigram findings of chronic pancreatitis and carcinoma of the pancreas were compared with endoscopic retrograde pancreatography (ERP) findings and Pancreozymin-Secretin test (P-S test). I) The frequency of pancreatic cancer was 93%, whilst, the chronic pancreatitis was 88% in the abnormal pancreatic scintigram. II) In the scintigram the type II (localized defect shadows) of pancreatic cancer was comparatively high and it is proportional to evidence derived from ERP. Localized diagnostic certainty is helpful, although the two tests are related. The P-S test is only restricted to the carcinoma of head, whilst, scintigram is more useful to detect the carcinoma of the body and tail of the pancreas. II) As for the chronic pancreatitis, there are various accumulative patterns. This is resemblance to that of ERP findings, but in the P-S normal test, it showed discrepancy in part of the result. Particularly, in the type I (slightly generalized low uptake with density silhouette) and type II. Therefore in order to obtain an accurate diagnosis, it is essential to have both the P-S test and scintigram.
mesh_terms: D002760:Cholangiopancreatography, Endoscopic Retrograde; D002766:Cholecystokinin / Q000627:therapeutic use; D002908:Chronic Disease; D005069:Evaluation Studies as Topic; D006801:Humans; D010179:Pancreas / Q000000981:diagnostic imaging*; D010190:Pancreatic Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging*; D010195:Pancreatitis / Q000175:diagnosis / Q000000981:diagnostic imaging*; D011877:Radionuclide Imaging; D012633:Secretin
chemical_list: D012633:Secretin; D002766:Cholecystokinin